CPT 55700 Is Gone: Your 2026 Guide to Prostate Biopsy Billing & Coding

Free Practice Audit

A prostate biopsy claim can be clinically appropriate and still get denied if the code, the diagnosis, the documentation, or the payer's rules don't line up. For 2026, that risk went up for one specific reason: the code most urology practices used for prostate biopsies for decades, CPT 55700, is no longer valid.

CPT 55700 (“Biopsy, prostate; needle or punch, single or multiple, any approach”) was deleted effective January 1, 2026. The AMA CPT Editorial Panel replaced it with a family of more specific codes — 55705 through 55715 — that separate biopsies by approach, imaging guidance, and whether sampling is systematic or targeted to a specific lesion. Any 2026 claim still billed under 55700 will not process correctly.

This guide walks through what changed, how to select the right replacement code, what documentation each one requires, and where prostate biopsy claims tend to run into trouble.

Quick Answer: What Happened to CPT 55700?

CPT 55700 was deleted effective January 1, 2026. It has been replaced by an expanded family of codes (55705–55715) that report prostate biopsies based on approach (transrectal vs. transperineal), imaging guidance (none, ultrasound, MRI-ultrasound fusion, or in-bore CT/MRI), and whether the sampling is systematic or targeted to a specific lesion. Code selection now depends heavily on what the operative note actually documents.

CPT 55700 at a Glance

 

Billing Element	What to Review
Code status	55700 is deleted for 2026 — confirm no system still defaults to it
Replacement family	55705–55715, selected by approach and imaging guidance
Procedure match	Confirm the operative note supports the specific code chosen
Diagnosis	Ensure the diagnosis reflects the documented clinical reason for biopsy
Documentation	Approach, imaging method, and lesion count must be clearly recorded
Imaging guidance	Bundled into the new codes — verify before billing separately
Modifiers	Apply only when the encounter and payer policy actually support it
Payer	Confirm each payer's system recognizes the new code family

The New Prostate Biopsy Code Family (55705–55715)

Rather than one broad code covering every approach, 2026 billing now requires matching the claim to the specific technique documented. At a general level, the replacement family distinguishes between:

•     Non-image-guided biopsy, any approach (a revised, retained code)

•     Transperineal template/saturation biopsy (a retained, distinct code)

•     Transrectal, ultrasound-guided biopsy — systematic sampling

•     Transrectal, ultrasound-guided biopsy with MRI-fusion guidance to a targeted lesion

•     Transperineal, ultrasound-guided biopsy — systematic sampling

•     Transperineal, ultrasound-guided biopsy with MRI-fusion guidance to a targeted lesion

•     Transrectal or transperineal MRI-ultrasound fusion-guided biopsy, targeted lesion(s) only

•     In-bore CT- or MRI-guided targeted biopsy

•     An add-on code for each additional targeted lesion biopsied via fusion or in-bore imaging, reported with the primary code

Because the exact descriptor language, numbering, and add-on rules for each of these codes come directly from the current AMA CPT code book, coders should confirm the precise descriptor and sequencing for the code they intend to bill against the current CPT manual or a licensed CPT reference before submission — this guide is not a substitute for that lookup.

One structural change worth flagging for revenue cycle teams: imaging guidance that used to be billed as a separate ultrasound-guidance code alongside 55700 is now bundled into the new biopsy codes. Continuing to separately report standalone imaging-guidance codes alongside the new prostate biopsy family is one of the more likely sources of edit-driven denials in 2026.

When Should the New Codes Be Used?

Code selection should follow three questions, in order: what approach was used (transrectal or transperineal), what imaging guidance was involved (none, ultrasound, MRI-ultrasound fusion, or in-bore CT/MRI), and whether the sampling was systematic, targeted to a specific lesion, or both. The clinical reason for the biopsy — an elevated PSA, an abnormal exam finding, or a prior suspicious result — supports medical necessity, but it does not by itself determine which of the eleven codes applies. Two patients with the same indication can require two different codes if the approach or imaging differs.

CPT Prostate Biopsy Documentation Checklist

☐  Approach documented (transrectal or transperineal)

☐  Imaging guidance documented (none, ultrasound, MRI-fusion, or in-bore CT/MRI)

☐  Systematic sampling, targeted lesion biopsy, or both clearly described

☐  Number of targeted lesions documented when applicable

☐  Medical necessity supported by documented clinical findings

☐  Diagnosis reflects the actual documented condition or finding

☐  Physician/professional involvement documented

☐  Specimen and any relevant pathology handoff information noted

☐  Complications or unusual circumstances documented when they occurred

☐  Payer-specific documentation requirements reviewed

This is a workflow aid, not a substitute for the current CPT descriptor or payer-specific requirements — always verify both directly.

ICD-10-CM Diagnosis Coding for Prostate Biopsy Claims

The diagnosis reported should reflect exactly what's documented — an elevated PSA, an abnormal digital rectal exam finding, a suspicious imaging finding, or an already-established prostate condition — not whatever code seems most likely to get the claim paid. An elevated PSA is a lab finding, not a cancer diagnosis, and should not automatically be coded as if a cancer diagnosis has been established. When pathology later confirms a specific condition, subsequent claims should reflect that updated, documented diagnosis rather than carrying forward an earlier working diagnosis by default.

Clinical Documentation	Coding Consideration
Abnormal lab finding documented (e.g., elevated PSA)	Code the documented abnormal finding, not a presumed diagnosis
Prostate-related symptom documented	Code the documented symptom when that's what the record supports
Previously established condition documented	Use the applicable established diagnosis code
Pathology-confirmed diagnosis documented	Follow current ICD-10-CM guidance for reporting the confirmed condition

These are educational examples, not universal coding rules — diagnosis selection should always be verified against the specific medical record and current ICD-10-CM guidelines.

Modifiers: What Billing Teams Should Check

None of the new prostate biopsy codes should automatically carry a modifier. Whether a modifier applies — for a significant, separately identifiable E/M service performed the same day, a distinct procedural circumstance, or a reduced or discontinued procedure — depends entirely on what actually happened during the encounter and on the specific payer's current policy. Appending a modifier to get past a claims edit, rather than because the documented circumstances support it, is a compliance risk, not a billing fix.

Global Period and Postoperative Considerations

The legacy 55700 code carried a zero-day global surgical period, meaning it did not bundle in follow-up office visits. Because the new 55705–55715 family was newly valued for the 2026 Medicare Physician Fee Schedule, practices should confirm the current global period assigned to whichever specific code they're billing rather than assuming it matches the old code, since CMS values and global-period assignments can differ across the eleven-code family.

Professional vs. Facility Billing for Prostate Biopsy

A prostate biopsy performed in an ambulatory surgery center or hospital outpatient setting typically involves both a professional claim (the physician's work) and a separate facility claim (the site of service's resources and supplies). A biopsy performed entirely in an office setting is usually billed differently, without a separate facility claim for that portion of care. Practices need to know which claim they're responsible for submitting in each setting, since a biopsy is not billed the same way in every site of service.

Prostate Biopsy and Related Services

Service/Component	Billing Question
Prostate biopsy code	Does the selected 2026 code match approach, imaging, and targeting as documented?
Imaging guidance	Is it bundled into the biopsy code, or was a separately reportable service actually performed and documented?
Pathology	Who performed the pathology service, and is it billed by that party?
Anesthesia	Was anesthesia separately provided, documented, and billed by the appropriate party?
Follow-up care	Is it included in the global period, separately reportable, or governed by payer-specific rules?

Never unbundle services simply because multiple clinical components occurred in the same encounter. Review the current CPT guidelines, NCCI edits, global-surgery rules, and the specific payer's policy before reporting anything separately.

Common Prostate Biopsy Billing Mistakes

Why Are Prostate Biopsy Claims Denied?

Denials on these claims tend to fall into a handful of recurring categories: a code that doesn't match the documented approach or imaging method, a diagnosis that doesn't support medical necessity, missing or vague operative documentation, an unsupported modifier, a payer-specific policy issue, a duplicate claim, an NCCI or bundling edit, an eligibility problem, or — when required by the applicable payer or plan — a missing authorization.

Denial Prevention Workflow

1. Eligibility

Confirm coverage and benefits before the procedure is scheduled or billed.

2. Medical Necessity

Verify the documented clinical reason supports the biopsy being performed.

3. Documentation

Confirm the note clearly states approach, imaging guidance, and targeting.

4. CPT/ICD-10 Review

Match the 2026 code and diagnosis to what's actually documented.

5. Modifier Check

Add a modifier only when the circumstances and payer policy support it.

6. Payer Rules

Confirm the specific payer's current policy for the code being billed.

7. Claim Scrubbing

Run the claim through edit checks before it leaves the building.

8. Submission

Submit a complete claim with required supporting documentation.

9. Denial Monitoring

Track denials by code and reason as they come in.

10. A/R Follow-Up

Work unresolved claims on a defined schedule rather than letting them age.

Fictional Billing Scenario

Fictional educational scenario — not a Sirius Solutions Global client case.

A urology practice documents an abnormal prostate-related finding and performs a transrectal, ultrasound-guided systematic biopsy in February 2026. The billing team submits the claim using the practice's old superbill, which still lists 55700. The claim is rejected because 55700 no longer exists for 2026 dates of service.

The billing team's review should include: confirming which 2026 code matches the documented approach and imaging, verifying the diagnosis against the medical record, checking whether any modifier applies, reviewing the specific payer's current policy for the corrected code, and checking claim history for related denials before resubmitting. Correcting the code doesn't guarantee payment on its own — it simply removes the most obvious barrier to the claim being considered.

Prostate Biopsy Claim: 10-Point Pre-Submission Check

☐  Correct 2026 code selected (not 55700)

☐  Current CPT descriptor for that code reviewed

☐  Documentation supports the approach and imaging billed

☐  Diagnosis matches the medical record

☐  Medical necessity clearly supported

☐  Modifiers reviewed against actual circumstances

☐  Bundling/NCCI considerations checked, especially for imaging guidance

☐  Payer policy verified for the specific code

☐  Authorization checked when required by the payer or plan

☐  Claim reviewed for edits before submission

5 Ways Urology Practices Can Strengthen Biopsy Billing in 2026

1.   Retire 55700 from every charge master, superbill, and EHR favorite list.

2.   Build a quick-reference grid mapping approach and imaging method to the correct 2026 code.

3.   Monitor clearinghouse rejections closely during the first several months of the transition.

4.   Track denial reasons by specific code, diagnosis, and payer to spot systemic issues fast.

5.   Review A/R aging on biopsy claims regularly rather than only after a denial spike.

Frequently Asked Questions

What is CPT 55700?

CPT 55700 was the code historically used for prostate needle or punch biopsies, regardless of approach. It was deleted effective January 1, 2026.

What is CPT 55700 used for now?

It isn't used for 2026 dates of service. Prostate biopsies are now reported using the replacement family of codes, 55705 through 55715, selected by approach and imaging guidance.

What documentation is required for the new prostate biopsy codes?

At minimum: the approach used, the imaging guidance (if any), whether sampling was systematic or targeted, the number of targeted lesions when applicable, and clear support for medical necessity.

What diagnosis codes may support a prostate biopsy?

Whatever the medical record actually documents — commonly an abnormal PSA or imaging finding, a suspicious exam finding, or an established condition. The specific code should be verified against current ICD-10-CM guidance rather than assumed.

Can the new prostate biopsy codes be billed with modifiers?

Only when the actual circumstances of the encounter and the applicable payer's policy support it. No modifier should be added automatically.

What causes prostate biopsy claim denials?

Common causes include billing a deleted code, a code that doesn't match the documented approach or imaging, diagnosis mismatches, missing documentation, unsupported modifiers, bundling issues, and payer-specific policy requirements.

Do the new codes include imaging guidance?

Imaging guidance is generally bundled into the new biopsy code family. Confirm current bundling rules before billing an imaging-guidance code separately.

How can urology practices prevent prostate biopsy billing errors?

Update every system reference from 55700 to the correct 2026 code, train coders on the approach/imaging decision logic, tighten documentation standards, and track denials by code so recurring issues get fixed at the source.

Prostate Biopsy Coding at a Glance

2026 Status: CPT 55700 deleted effective January 1, 2026

Replacement Family: CPT 55705–55715, selected by approach and imaging guidance

Critical Billing Focus: Matching the code to documented approach, imaging, and targeting

Biggest Risk: Legacy systems still defaulting to the deleted 55700 code

About Sirius Solutions Global

Sirius Solutions Global is a healthcare billing and revenue cycle management company supporting practices with insurance verification, claims submission, denial management, A/R follow-up, payment posting, patient billing support, and broader revenue cycle management services.

Learn more about our urology billing services or request a billing consultation.

Disclaimer

This article is provided for general informational and educational purposes only and does not constitute legal, medical, or coding advice. CPT is a registered trademark of the American Medical Association; CPT code numbers and descriptions referenced here have been paraphrased and are not reproduced verbatim from AMA copyrighted material. CPT, ICD-10-CM, Medicare, and payer requirements can change and vary by payer, plan, and clinical circumstance. Practices should verify current coding, coverage, and reimbursement information directly with the AMA, CMS, applicable Medicare Administrative Contractors, and individual payers, and should consult qualified coding, compliance, or legal professionals for guidance specific to their situation. Sirius Solutions Global does not guarantee coverage, payment, denial reduction, or specific financial results.